Apabetalone is under clinical development by Resverlogix and currently in Phase I for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD). According to GlobalData, Phase I drugs for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Apabetalone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Apabetalone overview

Apabetalone (RVX-208) is under development for the treatment of coronary artery disease, rheumatoid arthritis, peripheral artery disease, chronic kidney disease, retinal degeneration, pulmonary arterial hypertension,  vascular cognitive dementia, complement mediated disease, and coronavirus disease 2019 (COVID-19). It is administered orally.  It targets the BD2 domain of the BRD4 (bromodomain-containing protein 4) belonging to the BET (bromodomain and extra-terminal domain) family. The drug candidate is developed based on the company’s proprietary NexVas platform. It was also under development for the treatment of dyslipidemia and Alzheimer’s disease, rheumatoid arthritis, pre-diabetes mellitus and paroxysmal nocturnal hemoglobinuria.

It was under development for the treatment for fabry disease, vascular dementias, facioscapulohumeral muscular dystrophy (FSHD), human immunodeficiency virus infections, malignant peripheral nerve sheath tumors (MPNST) and cognitive disorders.

Resverlogix overview

Resverlogix is a biotechnology company that develops small molecule therapeutics for cardiovascular disease, diabetes mellitus and chronic kidney disease. The company’s lead product candidate includes Apabetalone (RVX-208) a first-in-class small molecule that inhibits BET bromodomain proteins for the treatment of high-risk cardiovascular disease and Alzheimer’s disease. Resverlogix utilizes an epigenetics drug development platform, BET technology that targets BET proteins and identifies small molecule candidates that specifically bind to BET bromodomains and regulate gene expression, among others. It also discovers and develops therapeutics for neurodegenerative diseases, peripheral artery disease and rare orphan diseases. The company operates in Canada and the US. Resverlogix is headquartered in Calgary, Alberta, Canada.

For a complete picture of Apabetalone’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.